>

Orphazyme Financials

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>OR</div>
ORPHA -- Denmark Stock  

DKK 90.80  14.00  13.36%

Understanding current and past Orphazyme Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. Use fundamental data analysis to confirm all available drivers of Orphazyme AS to find out if markets are presently mispricing the firm. We found twenty available financial ratios for Orphazyme AS, which can be compared to its competitors. To make sure the equity is not overpriced, please check all Orphazyme AS financials, including its Debt to Equity as well as the relationship between Cash Flow from Operations and Beta . Use Orphazyme to protect your portfolios against small markets fluctuations. The stock experiences very speculative upward sentiment. Check odds of Orphazyme to be traded at kr86.26 in 30 days.
View Fundamentals For
Refresh
With this module, you can determine Orphazyme financials for your investing period. You should be able to track the changes in Orphazyme individual fundamental values over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
26%26%

Chance of Financial Distress

Orphazyme AS has less than 26 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Orphazyme Company Summary

Orphazyme competes with Genmab AS, and . Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of orphan protein-misfolding diseases. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.
InstrumentDenmark Stock View All
ExchangeCopenhagen Stock Exchange
Business AddressOle Maaloes Vej 3
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.orphazyme.com
Phone45 39 17 82 72
CurrencyDKK - Danish Krone

Orphazyme Key Financial Ratios

Orphazyme Financial Ratios Relationships

Orphazyme AS is regarded third in cash flow from operations category among related companies. It is regarded third in return on asset category among related companies .

Orphazyme AS Systematic Risk

The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Orphazyme AS correlated with the market. If Beta is less than 0 Orphazyme generally moves in the opposite direction as compared to the market. If Orphazyme Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Orphazyme AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Orphazyme is generally in the same direction as the market. If Beta > 1 Orphazyme moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Orphazyme April 8, 2020 Opportunity Range

Please check Your Equity Center. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page